CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 5.0

ph-index = 4

Forward Citations = 95(Granted Patents)

Location History:

Fremont, CA (US) (2001 - 2006)
Hayward, CA (US) (2002 - 2021)

Company Filing History:

9 out of 523

Pharmacia & Upjohn Company

patents

4 out of 50

Onyx Therapeutics, Inc.

Altos Therapeutics, LLC

patents

6. 1 out of 832,680

Other

patents

Years Active: 2001-2021

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11077198 - Pegylated carfilzomib compounds (2021-08-03),

2. 10682419 - Prodrugs of peptide epoxy ketone protease inhibitors (2020-06-16),

3. 10675353 - Pegylated carfilzomib compounds (2020-06-09),

4. 10517954 - Pegylated carfilzomib compounds (2019-12-31),

5. 9878047 - Prodrugs of peptide epoxy ketone protease inhibitors (2018-01-30),

6. 9315542 - Prodrugs of peptide epoxy ketone protease inhibitors (2016-04-19),

7. 9309283 - Prodrugs of peptide epoxy ketone protease inhibitors (2016-04-12),

8. 9156840 - [object Object] (2015-10-13),

9. 8691836 - [object Object] (2014-04-08),

10. 7645781 - N-aryl-2-oxazolidinone-5-carboxamides and their derivatives (2010-01-12),

11. 7435751 - 7-Fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents (2008-10-14),

12. 7141588 - N-aryl-2-oxazolidinone-5-carboxamides and their derivatives (2006-11-28),

13. 7101874 - Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones (2006-09-05),

14. 7002020 - Oxazolidinone combinatorial libraries, compositions and methods of preparation (2006-02-21),

15. 6919329 - N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives (2005-07-19),

Title: **Gary W. Luehr: Innovator in Pharmaceutical Patents**

Introduction

Gary W. Luehr, based in Fremont, CA, has made significant contributions to the field of pharmaceuticals through his innovative inventions. With a remarkable portfolio of 21 patents, Luehr has focused on advancing treatments for complex medical conditions, particularly in oncology.

Latest Patents

Among his latest inventions are pegylated carfilzomib compounds, which provide a novel method for treating multiple myeloma. This invention features polymeric pegylated carfilzomib compounds and their pharmaceutically acceptable salts, offering new avenues for therapeutic applications. Additionally, Luehr has developed prodrugs of peptide epoxy ketone protease inhibitors, which showcase compounds useful as pro-drugs for enhancing therapeutic efficacy.

Career Highlights

Throughout his distinguished career, Gary W. Luehr has been associated with prominent companies in the pharmaceutical industry, including Pharmacia & Upjohn Company and Onyx Therapeutics, Inc. His work has been pivotal in developing new treatments and formulations that aim to improve patient outcomes.

Collaborations

In his innovative journey, Luehr has collaborated with various professionals in the field. Notably, he has worked alongside Mikhail Fedorovich Gordeev and Dinesh Vinoobhai Patel, contributing to a rich exchange of ideas and expertise that has advanced the development of pharmaceutical technologies.

Conclusion

Gary W. Luehr's extensive patent portfolio and collaborative efforts underscore his impact on the pharmaceutical landscape. Through his innovative inventions, he continues to play a vital role in the advancement of medical treatments, benefiting both the industry and patients alike.

This text is generated by artificial intelligence and may not be accurate.